Compare Gilead Sciences, Inc. (GILD) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Gilead Sciences, Inc. trades at $136.98 (market cap $168.35B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $61.82 (market cap $78.85B). The key difference: Gilead Sciences, Inc. is far larger — about 2.1× MONDELEZ INTERNATIONAL INC Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.24%). Which is the better fit depends on your goals.
| GILD | MDLZ | |
|---|---|---|
Market Cap | $168.35B | $78.85B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $64.99 |
52-Week Low | $110.56 | $51.51 |
Enterprise Value | $191.42B | $99.19B |
Dividend Yield | 2.42% | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
MDLZ trades at $61.53, down 1.72% today, with a bullish technical outlook supported by moving averages and oversold RSI signals. The company reported strong Q2 2026 earnings, beating estimates with $0.73 EPS and raising organic sales guidance, driven by growth in emerging markets. Valuation ratios like P/E of 37.75 and P/S of 4.01 reflect premium pricing, while profitability remains solid with an 8.86% net income margin.
The stock offers upside to the $70.50 consensus price target, supported by analyst optimism and institutional buying, but faces risks from reliance on international sales and margin pressures. Earnings momentum and dividend stability provide a favorable outlook, though macroeconomic volatility could challenge growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
